Medical/Pharmaceuticals
Ascletis Announces Co-formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical Development
- Using Ascletis' proprietary Ultra-Long-Acting Platform technology, co-formulation of ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, demonstrated a comparable pharmacokinet...
2025-11-13 07:30
1557
Laronix Secures $3.2 Million Grant from the Australian Government to Bring its AI-Powered Voice Technology to the Market
BRISBANE, Australia, Nov. 13, 2025 /PRNewswire/ -- Laronix
2025-11-13 06:30
1270
Focusing on Industrialisation and Exploring Global Pathways -- The 3rd CREATE Symposium Concludes Successfully
HONG KONG, Nov. 12, 2025 /PRNewswire/ -- How is artificial intelligence revolutionising diagnostic experiences? How can robotics enhance surgical precision? How far are we from achieving universal access to medical AI? What are the latest trends and future directions in medical technology develo...
2025-11-12 21:20
1110
Medit and OraQ Announce Strategic Partnership to Advance AI-Driven Intelligence in Digital Dentistry
Collaboration unites two leaders in innovation to redefine how clinical insight is delivered across the dental ecosystem NEWPORT BEACH, Calif., Nov. 12, 2025 /PRNewswire/ -- Medit, a global leader in 3D intraoral scanning solutions, and OraQ, a pioneer in AI-powered clinical intelligence, today ...
2025-11-12 21:00
1188
EirGenix Signed The Commercial Licensing Agreement for Its Second HER2 Biosimilar Asset EG1206A
TAIPEI, Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (SIX:SDZ/OTCQX:SDZNY) for the commercialization of its independently developed breast cancer biosim...
2025-11-12 20:47
1438
EirGenix Signed The Commercial Licensinse Agreement for It's Second HER2 Biosimilar Asset EG1206A
TAIPEI, Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (SIX:SDZ/OTCQX:SDZNY) for the commercialization of its independently developed breast cancer biosim...
2025-11-12 16:12
1015
Vieworks Completes Major Expansion of Hwaseong Manufacturing Site, Doubling Production Capacity
Strategic Infrastructure Growth Positions Vieworks at the Forefront of Global Imaging Innovation ANYANG, South Korea, Nov. 12, 2025 /PRNewswire/ -- Vieworks, a global leader in advanced X-ray imaging and industrial vision systems, has announced the successful completion of a large-scale expansio...
2025-11-12 10:44
1338
Alpha IVF Singapore uses Advanced Fertility Genomic Screening and Artificial Intelligence Embryo Scoring to help couples become parents
SINGAPORE, Nov. 12, 2025 /PRNewswire/ -- In-vitro fertilisation (IVF) has become increasingly prominent due to societal shifts towards delayed childbearing, infertility issues, and advances in medical technology that have improved success rates. At Alpha IVF Singapore, Advanced Fertility Genomic ...
2025-11-12 10:00
880
John Chuang and Onyx Healthcare Inc. Honored with Dual Wins at the Asia Pacific Enterprise Awards (APEA) 2025 Taiwan Chapter
TAIPEI, Nov. 12, 2025 /PRNewswire/ -- Onyx Healthcare Inc., a global leader in medical AI computing and healthcare device manufacturing, proudly celebrates its dual victory at the Asia Pacific Enterprise Awards (APEA) 2025 Taiwan Chapter, receiving accolades under the Corporate Excellence and Mas...
2025-11-12 09:00
851
CureGene Unveils Groundbreaking Preclinical Data for CG-0416, a Novel Oral Non-GLP-1 Therapy, at Obesity Week 2025
CG-0416, a highly liver-targeted THR-β agonist, demonstrates high-quality weight loss by reducing fat mass while preserving muscle, both as a monotherapy and in combination withGLP-1 RAs. ATLANTA, Nov. 11, 2025 /PRNewswire/ -- CureGene Pharmaceuticals ("CureGene") today announced the first discl...
2025-11-12 06:24
2066
OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer
MELBOURNE, Australia and INDIANAPOLIS, Nov. 12, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that final positive results from the Phase 2 OPALESCENCE trial[1] of TLX250-CDx (89 Zr-girentuximab) in metastatic triple negative breast cancer (mTNB...
2025-11-12 04:00
1470
Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti® and Rexulti® driven by additional investments
VALBY, Denmark, Nov. 12, 2025 /PRNewswire/ -- Key highlights Lundbeck's total revenue grew by +14% CER[1] (+13% DKK) to DKK 18,537 million in the first nine months of 2025. Growth in the U.S. andEurope was the driver of this strong performance. * United States: DKK 9,955 million (+22% CER; +19...
2025-11-12 03:11
1420
From Bangkok to the World: Aura Bangkok Clinic Showcases International Standards in Aesthetic Care
BANGKOK, Nov. 11, 2025 /PRNewswire/ -- Aura Bangkok Clinic, a leader in Thailand's medical aesthetic industry, is enhancing the country's reputation as a top destination for Thai beauty medical tourism through its global expertise, award-winning services, and internationally recognized training p...
2025-11-11 22:00
1205
Strategic Partnership Between Sanyou Bio and Yugong Bio to Accelerate Expansion in High-End Synthetic Enzyme Market
SHANGHAI, Nov. 11, 2025 /PRNewswire/ -- Sanyou Bio and Yugong Bio today announced the signing of a strategic cooperation agreement. This powerful alliance marks a significant step to deepen their collaboration in the development of high-end synthetic molecular enzymes. This collaboration is base...
2025-11-11 22:00
1316
Mabwell's Novel Anti‑IL‑11 Monoclonal Antibody 9MW3811 Approved by NMPA to Initiate Phase II Clinical Trial in Pathological Scarring
SHANGHAI, Nov. 11, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its novel anti‑IL‑11 monoclonal antibody 9MW3811 has received approval from the China National Medical Products Administration (NMPA) to initiate...
2025-11-11 22:00
1307
The Sigourney Award-2025 Celebrates Four Recipients Honored for Creative Trailblazing Work Expanding Psychoanalytic Thought Globally
Interdisciplinary Work from Israel, Uruguay, and the United States Earns The Prestigious Sigourney Award-2025 Prize SAN FRANCISCO, Nov. 11, 2025 /PRNewswire/ -- The trailblazing work of four recipients has won The Sigourney Award-2025, earning international recognition and a substantial cash pri...
2025-11-11 21:11
1148
SOPHiA GENETICS and Element Biosciences Unite Sequencing Power and AI Analytics to Accelerate Global Research In Precision Medicine
BOSTON and SAN DIEGO, Nov. 11, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and Element Biosciences, Inc., a biology company transforming the pace and accessibility of scientific discovery, today announced at theAssociation for Molecular Pa...
2025-11-11 21:01
997
Coreline Soft Selected as Exclusive AI Provider for France's National Lung Cancer Screening Pilot Project, IMPULSION
- APHP-led IMPULSION project secures Coreline Soft as sole AI supplier
- UGAP (France's central public procurement agency) registration completed,
opening opportunities withFrance's largest public hospitals
SEOUL, South Korea, Nov. 11, 2025 /PRNewswire/ -- Coreline Soft
2025-11-11 21:00
1069
Waters Boosts Lab Productivity and Sample Throughput with Launch of its Charged Aerosol Detector Designed for Empower Software
* Drives efficiency and reliability in Quality Control and Development environments, integrating seamlessly with world-class Empower™ Chromatography Data System (CDS). * Mitigates CDS communication errors encountered in up to 70% of multi-vendor LC-CAD configurations.1 * Delivers near-unive...
2025-11-11 21:00
1153
MGI Tech Joins Forces with SAMRC and DSTI to Launch South Africa's 110K Human Genome Program and Unveil Africa's First DNBSEQ-T7, Ushering a New Era in African Genomics
CAPE TOWN, South Africa, Nov. 11, 2025 /PRNewswire/ -- MGI Tech Co., Ltd., a company dedicated to developing core tools and technologies that drive innovation in life sciences, today announced two historic milestones in African genomics: the official unveiling of the continent's first DNBSEQ-T7 s...
2025-11-11 17:40
1133
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 317 media titles]
2026-01-23 11:03
Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 308 media titles]
2026-01-27 13:00
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 306 media titles]
2026-01-23 09:00Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Nokia Strengthens Edge AI Capabilities Through Strategic Collaboration with Blaize on Hybrid Inference Solutions Across Asia Pacific Regions
[Picked up by 292 media titles]
2026-01-27 18:00
